| ADR Ontology |
| ADR Term |
Hyperhomocysteinaemia |
| ADR ID |
BADD_A08020 |
| ADR Hierarchy |
|
| Description |
Condition in which the plasma levels of homocysteine and related metabolites are elevated (>13.9 μmol/l). Hyperhomocysteinemia can be familial or acquired. Development of the acquired hyperhomocysteinemia is mostly associated with vitamins B and/or folate deficiency (e.g., PERNICIOUS ANEMIA, vitamin malabsorption). Familial hyperhomocysteinemia often results in a more severe elevation of total homocysteine and excretion into the urine, resulting in HOMOCYSTINURIA. Hyperhomocysteinemia is a risk factor for cardiovascular and neurodegenerative diseases, osteoporotic fractures and complications during pregnancy. [MeSH] |
| MedDRA Code |
10051286 |
| MeSH ID |
D020138
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Hyperhomocysteinaemia | Hyperhomocysteinemia | Hyperhomocysteinemias |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Not Available | Not Available | Not Available |
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D00623 | Dexamethasone | 0.000687% | | | BADD_D01580 | Nitrous oxide | 0.000788% | | | BADD_D01834 | Prednisone | 0.000040% | |
| The 1th Page 1
Total 1 Pages
|
|
